Comparing laser treatment to tranexamic acid for melasma
Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid in Combination With Topical Hydroquinone for Refractory Melasma
This study is testing whether laser treatment or a medication called tranexamic acid works better to help people with stubborn melasma improve their skin color and appearance.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Egymedicalpedia Industry-sponsored |
| Locations | 1 site (Aswān) |
| Trial ID | NCT06522984 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of fractional Erbium YAG laser treatment versus intradermal and systemic tranexamic acid for patients suffering from refractory melasma. Melasma is a skin condition characterized by brownish or grayish patches, primarily affecting women and those with darker skin types. The trial aims to evaluate the efficacy of these two treatment modalities in reducing pigmentation and improving skin appearance. Participants will be monitored for treatment outcomes and any side effects associated with the interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals of both sexes diagnosed with melasma.
Not a fit: Patients who are pregnant, lactating, or have a history of thrombosis or hypersensitivity to tranexamic acid or hydroquinone may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients suffering from refractory melasma.
How similar studies have performed: While there have been studies on both laser treatments and tranexamic acid for melasma, this specific comparison is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients of both sexes with melasma. Exclusion Criteria: * Pregnancy * Lactation * Administration of oral contraceptive pills or any phototoxic drug within 1 month prior to study * Patients with a history of thrombosis, abnormal bleeding profile, known hypersensitivity to TA or HQ, and endocrinal disease.
Where this trial is running
Aswān
- Aswan University hospitals — Aswān, Egypt (Recruiting)
Study contacts
- Study coordinator: Heba Allah Mohamed Mustafa, Resident
- Email: HebaAllah1704336@aswu.edu.eg
- Phone: +201151182890
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.